{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:08:46Z","timestamp":1774325326702,"version":"3.50.1"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Oncolytic viruses are a unique modality with multifaceted mechanisms of action for killing cancer cells and have been developed as a promising therapeutic approach in cancer treatment. The first-in-class agent, talimogene laherparepvec (T-VEC), has shown clinical benefit in patients with advanced melanoma. However, intratumoral administration of oncolytic viruses has several limitations which prevent use against a broader range of cancer types. Here, we propose a novel treatment strategy consisting of the intravenous administration of a genetically engineered oncolytic adenovirus type 11 (Ad11) mixed with anti-Ad11 neutralizing monoclonal antibodies. Ad11, which has minimum binding affinity to human erythrocytes, was modified to selectively replicate in cancer cells. New anti-Ad11 antibody clones were generated which inhibit binding between Ad11 fibers and their natural receptor, CD46. The neutralizing antibodies suppressed viral accumulation in the lungs by about 10-fold in human CD46-transgenic mice without loss of infectivity to cancer cells. Our findings are important in ensuring safe and efficient virus delivery following intravenous administration in humans and may expand treatment options.<\/jats:p>","DOI":"10.1371\/journal.pone.0326857","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T18:09:32Z","timestamp":1750874972000},"page":"e0326857","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neutralizing monoclonal antibodies improve biodistribution of intravenously administered oncolytic adenovirus in human CD46-transgenic mice"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0925-5323","authenticated-orcid":true,"given":"Masahisa","family":"Hemmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3614-1289","authenticated-orcid":true,"given":"Midori","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7807-1269","authenticated-orcid":true,"given":"Shinsuke","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"9","key":"pone.0326857.ref001","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"HL Kaufman","year":"2015","journal-title":"Nature Reviews Drug Discovery"},{"issue":"2","key":"pone.0326857.ref002","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"N Macedo","year":"2020","journal-title":"J Immunotherapy Cancer"},{"issue":"1","key":"pone.0326857.ref003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003836","article-title":"From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer","volume":"10","author":"CS Ilkow","year":"2014","journal-title":"PLoS Pathog"},{"issue":"4","key":"pone.0326857.ref004","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","article-title":"Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines","volume":"33","author":"SJ Russell","year":"2018","journal-title":"Cancer Cell"},{"issue":"526","key":"pone.0326857.ref005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7992","article-title":"Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade","volume":"12","author":"S Nakao","year":"2020","journal-title":"Sci Transl Med"},{"issue":"4","key":"pone.0326857.ref006","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"BL Liu","year":"2003","journal-title":"Gene Ther"},{"issue":"25","key":"pone.0326857.ref007","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"RHI Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"13","key":"pone.0326857.ref008","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial","volume":"23","author":"RHI Andtbacka","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"pone.0326857.ref009","doi-asserted-by":"crossref","first-page":"834841","DOI":"10.3389\/fmolb.2022.834841","article-title":"Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class","volume":"9","author":"HL Kaufman","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"3","key":"pone.0326857.ref010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"SZ Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"pone.0326857.ref011","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1245\/s10434-021-10910-5","article-title":"Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience","volume":"29","author":"MJ Carr","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"pone.0326857.ref012","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s43856-022-00098-4","article-title":"Advances in oncolytic virotherapy","volume":"2","author":"SJ Russell","year":"2022","journal-title":"Commun Med (Lond)"},{"issue":"4","key":"pone.0326857.ref013","article-title":"Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy","volume":"9","author":"DH Shin","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"pone.0326857.ref014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010474","article-title":"Innate immune surveillance of the circulation: A review on the removal of circulating virions from the bloodstream","volume":"18","author":"SE Ander","year":"2022","journal-title":"PLoS Pathog"},{"issue":"4","key":"pone.0326857.ref015","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/13543784.17.4.555","article-title":"ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine","volume":"17","author":"RN Greenberg","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"issue":"7362","key":"pone.0326857.ref016","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"CJ Breitbach","year":"2011","journal-title":"Nature"},{"issue":"6","key":"pone.0326857.ref017","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1158\/2326-6066.CIR-21-0171","article-title":"Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients","volume":"10","author":"A Samson","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"15","key":"pone.0326857.ref018","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"R Vogels","year":"2003","journal-title":"J Virol"},{"issue":"9","key":"pone.0326857.ref019","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"P Abbink","year":"2007","journal-title":"J Virol"},{"issue":"12","key":"pone.0326857.ref020","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1517\/14712590903307388","article-title":"Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors","volume":"9","author":"SS Seregin","year":"2009","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"pone.0326857.ref021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002409","article-title":"Directed evolution generates a novel oncolytic virus for the treatment of colon cancer","volume":"3","author":"I Kuhn","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"pone.0326857.ref022","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"R Garcia-Carbonero","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"pone.0326857.ref023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","article-title":"A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)","volume":"7","author":"J-P Machiels","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"12","key":"pone.0326857.ref024","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003645","article-title":"Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial","volume":"9","author":"V Moreno","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"10","key":"pone.0326857.ref025","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.tim.2008.07.009","article-title":"Vaccinia virus morphogenesis and dissemination","volume":"16","author":"KL Roberts","year":"2008","journal-title":"Trends Microbiol"},{"issue":"5","key":"pone.0326857.ref026","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/mt.2011.26","article-title":"Targeting tumor vasculature with an oncolytic virus","volume":"19","author":"CJ Breitbach","year":"2011","journal-title":"Mol Ther"},{"issue":"12","key":"pone.0326857.ref027","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2217\/imt.15.90","article-title":"Vaccinia virus, a promising new therapeutic agent for pancreatic cancer","volume":"7","author":"C Al Yaghchi","year":"2015","journal-title":"Immunotherapy"},{"issue":"14","key":"pone.0326857.ref028","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1073\/pnas.0711757105","article-title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo","volume":"105","author":"O Kalyuzhniy","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"pone.0326857.ref029","doi-asserted-by":"crossref","first-page":"9610","DOI":"10.1128\/JVI.01070-13","article-title":"Coagulation factor binding orientation and dimerization may influence infectivity of adenovirus-coagulation factor complexes","volume":"87","author":"EE Irons","year":"2013","journal-title":"J Virol"},{"issue":"3","key":"pone.0326857.ref030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"SN Waddington","year":"2008","journal-title":"Cell"},{"issue":"8","key":"pone.0326857.ref031","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tips.2012.04.005","article-title":"Adenovirus receptors: implications for targeting of viral vectors","volume":"33","author":"N Arnberg","year":"2012","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"pone.0326857.ref032","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nm0698-685","article-title":"Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo","volume":"4","author":"J Fueyo","year":"1998","journal-title":"Nat Med"},{"issue":"1","key":"pone.0326857.ref033","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"J Fueyo","year":"2000","journal-title":"Oncogene"},{"issue":"2","key":"pone.0326857.ref034","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ymthe.2004.05.020","article-title":"Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats","volume":"10","author":"CG Nicol","year":"2004","journal-title":"Mol Ther"},{"issue":"1","key":"pone.0326857.ref035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"N Ramesh","year":"2006","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"7","key":"pone.0326857.ref036","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/ijc.29536","article-title":"Treatment of melanoma with a serotype 5\/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans","volume":"137","author":"S Bramante","year":"2015","journal-title":"Int J Cancer"},{"issue":"6","key":"pone.0326857.ref037","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.18632\/oncotarget.2901","article-title":"Immunological data from cancer patients treated with Ad5\/3-E2F-\u039424-GMCSF suggests utility for tumor immunotherapy","volume":"6","author":"O Hemminki","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"pone.0326857.ref038","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0092-8674(00)80050-1","article-title":"Measles virus infection in a transgenic model: virus-induced immunosuppression and central nervous system disease","volume":"98","author":"MB Oldstone","year":"1999","journal-title":"Cell"},{"issue":"4","key":"pone.0326857.ref039","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1128\/JVI.80.4.1897-1905.2006","article-title":"The Arg279Gln [corrected] substitution in the adenovirus type 11p (Ad11p) fiber knob abolishes EDTA-resistant binding to A549 and CHO-CD46 cells, converting the phenotype to that of Ad7p","volume":"80","author":"DJ Gustafsson","year":"2006","journal-title":"J Virol"},{"issue":"16","key":"pone.0326857.ref040","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1128\/JVI.00754-08","article-title":"Structural variations in species B adenovirus fibers impact CD46 association","volume":"82","author":"L Pache","year":"2008","journal-title":"J Virol"},{"issue":"6382","key":"pone.0326857.ref041","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"A Ribas","year":"2018","journal-title":"Science"},{"issue":"12","key":"pone.0326857.ref042","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"A Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"pone.0326857.ref043","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","article-title":"New immune cell engagers for cancer immunotherapy","volume":"24","author":"A Fenis","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"pone.0326857.ref044","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0166-3542(01)00136-X","article-title":"Current research on respiratory viral infections: Third International Symposium","volume":"50","author":"AC Schmidt","year":"2001","journal-title":"Antiviral Research"},{"issue":"2","key":"pone.0326857.ref045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cll.2014.02.011","article-title":"Emerging respiratory viruses other than influenza","volume":"34","author":"JJ Dunn","year":"2014","journal-title":"Clin Lab Med"},{"issue":"1","key":"pone.0326857.ref046","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41426-018-0197-8","article-title":"Broadly neutralizing monoclonal antibodies against human adenovirus types 55, 14p, 7, and 11 generated with recombinant type 11 fiber knob","volume":"7","author":"X Tian","year":"2018","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"pone.0326857.ref047","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1099\/0022-1317-40-1-45","article-title":"Infection of mouse liver by human adenovirus type 5","volume":"40","author":"SJ Duncan","year":"1978","journal-title":"J Gen Virol"},{"issue":"5","key":"pone.0326857.ref048","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1073\/pnas.88.5.1651","article-title":"A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia","volume":"88","author":"HS Ginsberg","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0326857.ref049","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/cgt.2014.64","article-title":"A novel immunocompetent murine model for replicating oncolytic adenoviral therapy","volume":"22","author":"L Zhang","year":"2015","journal-title":"Cancer Gene Ther"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T18:09:43Z","timestamp":1750874983000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326857"}},"subtitle":[],"editor":[{"given":"Tomoko","family":"Fujiyuki","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0326857","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]}}}